Follow the Advaxis, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 1 February 2016 (Attribution). Among the most active insiders: O'Connor Daniel. All data is free.
20
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Advaxis, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental score
Ranked 24,849 of 29,053 companies
26.3
score / 100
Value
23
Quality
30
FCF yld-4.0%
Earn yld-5.1%
EV/EBITDA·
ROE-40%
Gross mgn36%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Advaxis, Inc. is a biopharmaceutical company that develops immunotherapy treatments for cancer. It focuses on using DNA technology to stimulate the immune system.